SCHEMBL8532155

SCHEMBL8532155

CN1CSC(Cc2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.44
KDM4E B2RXH2 4/20 0.44
MAPT P10636 4/20 0.44
TSHR P16473 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 3/20 0.42
CYP1A2 P05177 3/20 0.42
CYP3A4 P08684 2/20 0.42
MAPK1 P28482 2/20 0.42
BLM P54132 2/20 0.42
ATM Q13315 2/20 0.42
HIF1A Q16665 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CYP2C9 P11712 2/20 0.42
GMNN O75496 1/20 0.42
GABBR2 O75899 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
NFKB1 P19838 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7796811 0.86 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL7703145 0.83 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL8532773 0.83 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL8933311 0.81 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL8533919 0.80 GAA (0.42) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL7563154 0.80 MAOB (0.46) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL9486345 0.80 CAPN1 (0.34) ALDH1A1LMNACYP2C9ALOX15HSD17B10
SCHEMBL8933313 0.80 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTTSHRKMT2A
SCHEMBL7560742 0.79 CACNA1A (0.43) ALDH1A1KDM4EMAPTTSHRMEN1
SCHEMBL7561509 0.78 KMT2A (0.39) ALDH1A1KDM4ETSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
EP-0391644-B1 Aryl-substituted rhodanine derivatives LILLY CO ELI (US) 1996-06-19 EP disclosed
US-5387690-A Method of treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1995-02-07 US disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed